RXBAR Founder Peter Rahal: Revenue Reaches $300 Million in Two Years
In the latest episode of the business interview podcast "Founders" hosted by David Senra, RXBAR co-founder and current CEO of Medici Brands, Peter Rahal, detailed the process of restarting his entrepreneurial journey after selling RXBAR and achieving $300 million in revenue for his protein bar brand David within two years. He disclosed specific details about company financing, mergers, and organizational management.
Rahal founded RXBAR in 2013 with $10,000 in his parents' kitchen, generating $2 million in revenue and achieving profitability in the first year. Revenue grew to $6.5 million in the second year and reached $161 million in the fourth year. In 2017, RXBAR was sold to Kellogg's for $600 million, with Rahal holding about 50% of the shares and cashing out approximately $300 million before taxes. He remained with the company until May 2018 and, after a five-year non-compete period that ended in October 2022, he spent a year on product development, officially launching the new brand David protein bars in September 2024.
Medici Brands has rapidly secured financing—completing a $10 million seed round in 2024 (with Rahal investing $6 million, alongside investors including Dr. Peter Attia and neuroscientist Andrew Huberman), followed by a $75 million Series A round led by Greenoaks and Valor Equity Partners in May 2025, and a $250 million Series B round in September 2026, also led by Greenoaks and Valor, with participation from ICONIQ and Imaginary Ventures, bringing the company's valuation to $2.25 billion. The company has already launched David protein bars, a candy brand HallPass set to debut in Walmart in August 2026, and plans to introduce a third brand, Rowdy, within 2026.
In May 2025, David Protein used Series A funds to acquire core ingredient supplier Epogee, obtaining rights to its patented fat substitute EPG, which has only 0.7 calories per gram, a reduction of about 92% compared to traditional fats at 9 calories. The acquisition aimed to achieve vertical integration of the supply chain. This transaction led to an antitrust lawsuit filed on June 2, 2025, in the Southern District of New York, with plaintiffs Own Your Hunger, Lighten Up Foods, and Defiant Foods accusing David of monopolizing access to EPG ingredients through "secret and collusive" means, seeking a temporary injunction. The three plaintiffs claimed to have lost approximately $107,000 in sales and invested about $449,000 in R&D, with ongoing losses of about $15,000 per month; lawyers noted that antitrust lawsuits surrounding proprietary ingredients are "extremely rare" in the fast-moving consumer goods industry.
In addition to its core protein bar business, David launched a controversial marketing initiative in 2026—selling 6-ounce portions of wild Pacific cod frozen fish fillets, with four fillets priced at $55, officially positioned as "having slightly higher protein content per calorie than a David protein bar," aimed at creating buzz and reaching fitness enthusiasts willing to pay a premium for traceable, high-freshness protein sources. Currently, David protein bars are available in over 35,000 retail locations including Walmart, Target, and Costco, with projected revenue exceeding $300 million in 2026, making it the fastest brand in its category to reach this revenue milestone.
From a funding perspective, the Series B financing for Medici Brands was co-led by Greenoaks and Valor Equity Partners, with participation from ICONIQ, Imaginary Ventures, and founder Rahal himself, indicating a strong alignment of interests between the founder and institutional investors. This round of financing is clearly driven by the company's performance (achieving $300 million in revenue within two years and expanding to 35,000 stores), rather than relying solely on market sentiment. Beneficiaries include early seed and Series A investors like Greenoaks and Valor, with valuations skyrocketing from $725 million post-Series A to $2.25 billion in Series B, significantly enhancing returns. The pressured parties are small to medium competitors involved in lawsuits surrounding EPG ingredients, facing R&D and sales losses due to restricted access to ingredients.
Public information shows that Greenoaks and Valor Equity Partners previously co-led David's $75 million Series A round, with a valuation of about $725 million at that time; less than a year and a half later, the $250 million Series B round pushed the valuation to $2.25 billion, more than doubling. Additionally, Medici's HallPass brand launched in Walmart in August 2026, with the third brand Rowdy planned for release in 2026.
Source: Public Information
ABAB AI Insight
Rahal's entrepreneurial path itself serves as a replicable historical case study—starting RXBAR in 2013 with $10,000 from his parents' kitchen, achieving $2 million in revenue and profitability in the first year, reaching $161 million in the fourth year, and selling it to Kellogg's for $600 million in 2017, resulting in a personal pre-tax cash-out of about $300 million. Notably, he did not cash out and exit like most founders; instead, he immediately re-entered the market after the five-year non-compete period, creating a new company with nearly the same category (protein bars) and similar product logic (high protein, low sugar, simple ingredient list). This "sell and replicate" approach is uncommon among consumer goods founders.
The financing rhythm of David/Medici Brands reflects capital's preference and path dependence on "proven founders"—$10 million in seed funding, $75 million in Series A, and a direct jump to $250 million in Series B, with valuation soaring from $725 million post-Series A to $2.25 billion in just over a year. Lead investors Greenoaks and Valor Equity Partners have increased their stakes in consecutive rounds, motivated by Rahal's proven ability to scale from zero to millions, and institutions are willing to pay a premium for a "replicable founder strategy." A critical capital move was the acquisition of upstream ingredient supplier Epogee using Series A funds in May 2025, reclaiming bargaining power that originally belonged to the supply chain, which is a typical example of using capital to gain control over the supply chain rather than merely expanding capacity.
The most direct historical analogy is Rahal's own RXBAR—his two entrepreneurial ventures have nearly replicated the same strategy: minimal ingredient lists, high-protein positioning, and direct channel expansion, with the only difference being a proactive upstream vertical integration and more aggressive marketing tactics (such as selling frozen cod to create buzz). In terms of industry positioning, Medici Brands is at the stage of "founder IP" in the consumer goods sector—company valuation and financing capabilities are increasingly reliant on the credibility established by the founder's past exit records rather than solely on the market performance of a single brand. This is why the company has been able to incubate three brands—David, HallPass, and Rowdy—within two years while maintaining a steady financing pace.
Essentially, this represents a concentration of capital—financing resources in the consumer goods sector are shifting from "betting on a single hit brand" to "betting on founder platforms with successful exit records." Rahal has evolved from a single product founder to a multi-brand incubation platform operator, with institutional capital (Greenoaks, Valor, etc.) placing their bets on the replicability of the founder's capabilities rather than the lifecycle of a single product. This concentration occurs because the product barriers in consumer goods are low and easily replicable; only founders who can repeatedly scale products into successful businesses possess the scarce experience that capital is willing to pay a premium for, far exceeding the valuation logic of a single brand. The antitrust lawsuit triggered by the EPG ingredient acquisition further confirms this point—controlling access to the supply chain is becoming one of the means to build brand barriers.
ABAB News · Cognitive Laws
- Exit is not the end; it is the second execution of the same strategy.
- Capital buys not products, but reusable founders.
- When brands lack a moat, the supply chain becomes the new moat.